Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Dow
Colorcon
Medtronic
Boehringer Ingelheim
Harvard Business School
Baxter

Last Updated: November 28, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR BALSALAZIDE DISODIUM

➤ Subscribe for complete access

« Back to Dashboard

All Clinical Trials for balsalazide disodium

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00269438 ↗ New Tablet Formulation and Dosing Regimen of Balsalazide Disodium in Mildly to Moderately Active Ulcerative Colitis Completed Bausch Health Americas, Inc. Phase 3 2005-12-01 The purpose of this study is to establish the efficacy and safety of a new tablet formulation and dosing regimen of balsalazide disodium dosed twice daily in achieving clinical improvement in subjects with mildly to moderately active ulcerative colitis after 8 weeks of therapy.
NCT00269438 ↗ New Tablet Formulation and Dosing Regimen of Balsalazide Disodium in Mildly to Moderately Active Ulcerative Colitis Completed Valeant Pharmaceuticals International, Inc. Phase 3 2005-12-01 The purpose of this study is to establish the efficacy and safety of a new tablet formulation and dosing regimen of balsalazide disodium dosed twice daily in achieving clinical improvement in subjects with mildly to moderately active ulcerative colitis after 8 weeks of therapy.
NCT00408174 ↗ Balsalazide Disodium vs. Mesalamine in Mildly to Moderately Active Ulcerative Colitis Completed Bausch Health Americas, Inc. Phase 3 2006-05-01 To establish the efficacy and safety of a new tablet formulation and dosing regimen of balsalazide disodium dosed twice daily in achieving clinical improvement in subjects with mildly to moderately active ulcerative colitis after 6 weeks of therapy.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for balsalazide disodium

Condition Name

Condition Name for balsalazide disodium
Intervention Trials
Ulcerative Colitis 5
Healthy 2
Inflammatory Bowel Disease 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for balsalazide disodium
Intervention Trials
Colitis, Ulcerative 5
Colitis 3
Ulcer 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for balsalazide disodium

Trials by Country

Trials by Country for balsalazide disodium
Location Trials
United States 90
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for balsalazide disodium
Location Trials
Texas 5
New York 3
Illinois 3
Georgia 3
Louisiana 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for balsalazide disodium

Clinical Trial Phase

Clinical Trial Phase for balsalazide disodium
Clinical Trial Phase Trials
Phase 3 3
Phase 1 2
N/A 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for balsalazide disodium
Clinical Trial Phase Trials
Completed 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for balsalazide disodium

Sponsor Name

Sponsor Name for balsalazide disodium
Sponsor Trials
Bausch Health Americas, Inc. 3
Valeant Pharmaceuticals International, Inc. 3
Roxane Laboratories 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for balsalazide disodium
Sponsor Trials
Industry 10
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Merck
Moodys
Medtronic
Colorcon
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.